Home Cart 0 Sign in  

[ CAS No. 198904-31-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 198904-31-3
Chemical Structure| 198904-31-3
Structure of 198904-31-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 198904-31-3 ]

Related Doc. of [ 198904-31-3 ]

Alternatived Products of [ 198904-31-3 ]

Product Details of [ 198904-31-3 ]

CAS No. :198904-31-3 MDL No. :MFCD08435966
Formula : C38H52N6O7 Boiling Point : -
Linear Structure Formula :- InChI Key :AXRYRYVKAWYZBR-GASGPIRDSA-N
M.W : 704.86 Pubchem ID :148192
Synonyms :
BMS-232632;CGP 73547;Reyataz;Zrivada;Latazanavir
Chemical Name :1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate

Safety of [ 198904-31-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 198904-31-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 198904-31-3 ]

[ 198904-31-3 ] Synthesis Path-Downstream   1~88

  • 1
  • [ 162537-11-3 ]
  • 1-[4-(pyridin-2-yl)phenyl]-4(S)-hydroxy-5(S)-2,5-diamino-6-phenyl-2-azahexane trihydrochloride [ No CAS ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
84% With 4-methyl-morpholine; diisopropyl-carbodiimide; In dichloromethane; isopropyl alcohol; at -10 - 20℃;Inert atmosphere;Product distribution / selectivity; Example 1 : Preparation of atazanavir using 1 equivalent of compound (II), 3.5 equivalents of compound (III), 3.5 equivalents of DIC, and 6.6 equivalents of NMM97.5 g of 1 -[4-(piridyn-2-yl)phenyl-4(S)-hydroxy]-5-(S)-2,5-diamino-6-phenyl- 2-azahexane trihydrochloride (trihydrochloride of compound (II) with a 10%wt content of isopropanol, 185.97mmol) were suspended into 683 ml of dichloromethane under nitrogen atmosphere at -10 0C. 135 ml_ (1227.40 mmol) of /V-methylmorpholine were added maintaining the temperature at -10 0C.Separately, 100.8 ml_ (650.90 mmol) of N,N-diisopropylcarbodiimide were added to a suspension of 123.2 g (650.90 mmol) of N-(methoxycarbonyl)-L- tert-leucine (compound (III)) into 975 ml of dichloromethane.Then, the first suspension was quickly transferred over the second one. The resulting mixture was warmed up to room temperature and was maintained at such temperature until the reaction was completed (93% atazanavir by HPLC, monoimpurity content: 1.2%). The reaction mixture was filtered off and was washed with 800 ml_ of water. Then, the organic phase was concentrated up to half volume and 500 ml_ of tert-butylmethylether were added. The mixture was concentrated again up to half volume. This operation was repeated three times up to a dichloromethane content equal or less to 20%. The precipitated product was recovered by filtration. 125.4 g of atazanavir were obtained (Yield =96%). Purity by High Performance Liquid Chromatography (HPLC) = 98.2%, with 4% of N,N-diisopropylurea (DIU) and free of the other probable diastereomers. Molar yield =92%. Recrystallization in ethanol/water 45:55 yielded 105.34 g of atazanavir (149.5 mmol). Recrystallization yield: 84%. Purity HPLC = 99.4%, free of DIU, and free of the other probable diastereomers.The formula of the three probable diastereomers and the HPLC conditions to detect their presence are included below:d-ld-ll d-lHPLC conditions:Liquid chromatograph with UV detector equipped with automatic injector, and integration systemColumn: ZORBAX Eclipse XDB-C18 150x4.6 mm, 5mum.Mobile phase: A (0.05% formic acid in water) and B (ACN)Gradient elution:Detection: 254 nmFlow: 1 mL/minColumn temperature: 25 0CInjection: 2 muLTime injection and chromatogram: 20 minRelative retention time of the diastereomers (RRT):
  • 2
  • [ 857900-54-0 ]
  • [ 162537-11-3 ]
  • [ 198904-31-3 ]
  • 13
  • [ 857904-11-1 ]
  • [ 198904-31-3 ]
  • 15
  • [ 198904-31-3 ]
  • atazanavir sulphate [ No CAS ]
YieldReaction ConditionsOperation in experiment
95% With sulfuric acid; In acetone; at 0 - 50℃; for 2h; Example 2: Preparation of <strong>[198904-31-3]atazanavir</strong> sulfateA compound obtained as in Example 1 was transformed into the sulfate salt by addition of sulfuric acid following the process described in WO 9936404, in order to confirm that no racemization has been occurred following the process of the present invention. The confirmation was done by comparing the rotatory power of the <strong>[198904-31-3]atazanavir</strong> in form of sulfate salt obtained following the process of the present invention with the value known in the state of the art for <strong>[198904-31-3]atazanavir</strong> sulfate.172.8 g (245.16 mmol) of <strong>[198904-31-3]atazanavir</strong> and some crystals of <strong>[198904-31-3]atazanavir</strong> sulfate were suspended in 1728 ml acetone at 50 0C. 49 ml_ of sulfuric acid 5M (245.16 mmol) were quickly added and after a few minutes precipitation of a product was observed. It was maintained first at 50 0C during 1 hour, then at 25 0C during 30 min and, finally, at 0 0C during an additional 30 min. The solid was filtered off, washed with 170 ml_ of acetone and 170 ml_ of heptane, and dried under vacuum. 186.7 g (232.52 mmol) of <strong>[198904-31-3]atazanavir</strong> sulfate were obtained (yield: 95%, purity HPLC: 99.85%). [alpha]D : -45.3 (MeOH/H2O 1 :1 , 1 mg/mL). The rotatory power of <strong>[198904-31-3]atazanavir</strong> sulfate described in the literature is [CC]D : -46.1 (cf. Z. Xu et al., Organic Process Research & Development, 2002, vol. 6, pp. 323-328) which confirms that <strong>[198904-31-3]atazanavir</strong> base or its salts can be obtained by the process of the present invention efficiently without causing racemization.
95.2% With sulfuric acid; In ethanol; at 20 - 30℃; The purity is84.0% 41.9 g(Fold pure 35.2 g, 50.0 mmol) of <strong>[198904-31-3]atazanavir</strong> monomer was dissolved in 175 mL of ethanol,Stir the liquid at 20-30 C until clear and transparent,Poured into 80g containing activated 732 strong acid cation exchange resin column(Diameter 200mm, flow rate 2 ~ 3 drops / second)Dissociation and exchange, until the product is fully adsorbed to the resin, then use aboutThe resin was washed with 200 mL of ethanol and 400 mL of purified water to remove the adherent organic and inorganic impurities that did not adsorb to the resin. The resin column was eluted with 2% dilute sulfuric acid (1.2 L) at 20-30 C before dissociation and exchange (the eluate was detected by TLC until there was no <strong>[198904-31-3]atazanavir</strong> monomer), and the eluate was concentrated to the original volume 1/5 ~ 1/6, at 50 C by adding 0.3 grams of 767-type charcoal charcoal bleaching 20min, filtered, and then heated to the filtrate was added dropwise 200mL acetone, naturally reduced to 20-30 C, and then stirred for 5 ~ 6h, filtered , The filter cake was washed with 15mL acetone to give white powdery solid <strong>[198904-31-3]atazanavir</strong> 38.3g, yield 95.2%, HPLC purity of 99.9%
94% With sulfuric acid; pyrographite; In 1,2-dimethoxyethane; dimethyl sulfoxide; at 35℃;Inert atmosphere; <strong>[198904-31-3]Atazanavir</strong> free base (10 g, 14.19 mmol) was added to a mixed solvent of 150 mL ethylene glycol dimethyl ether and 8 mL DMSO.The temperature was raised in an argon atmosphere, and after the system was dissolved, 0.1 g of activated carbon was added for decolorization (system temperature was 50-60 C.) and filtered to obtain a clear solution.At a controlled temperature of 35 ± 5 C, the prepared clear solution was added dropwise with concentrated sulfuric acid (0.8 mL, 14.4 mmol);After dripping, heat and stir for 1 to 2 hours;Slowly (about 30 to 60 minutes) cool down to 0 to 15C, filter, filter cake is washed with ethylene glycol dimethyl ether 2 or 3 times, vacuum dried at 40 to 60C for 5 to 8 hours,That is, <strong>[198904-31-3]atazanavir</strong> sulfate 10.7g, the molar yield is 94.0%, the HPLC purity is >99.5%, and the maximum single impurity is <0.1%.
91% With sulfuric acid; In ethanol; tert-butyl methyl ether; at 20 - 30℃; for 4h; Example 3: 0.085 mL of sulfuric acid (concentrate, 1.1 equiv) was added into the mixture of 1 g of <strong>[198904-31-3]atazanavir</strong> base, 7.5 mL of EtOH (7.5 vol) and 7.5 mL of MTBE (7.5 vol) at 20-30 C. The resulting clear amber solution was stirred at 20-30 C. for 4 hr. The product was filtered, washed with a mixture of EtOH/MTBE (1:2, 3 mL, 3 vol), and dried under vacuum at 40-50 C. for 16 hr to afford <strong>[198904-31-3]atazanavir</strong> sulfate in Form A (1.04 g, 91% yield, 99.9% HPLC purity).
87.8% With sulfuric acid; In methanol; ethyl acetate; at 43℃; for 1h; Example 2: Preparation of compound (A) using ethyl acetate: methanol A solvent mixture of 500 ml of ethyl acetate and 50 ml of methanol was added to 100 gms of (3S,8S,9S,12S)-3,12- bis(l ,l-dimethylethyl)-8-hydroxy-4,l l-dioxo-9-(phenylmethyl)-6-[[4-(2- pyridinyl) phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester [Compound (II)]. The reaction mixture was stirred at a temperature of 27±2C to get a suspension. The temperature of the suspension was then raised to 43±2C and 7.5 ml (13.9 gms) of sulphuric acid was added slowly. The solution was maintained for an hour at a temperature of 43±2C whereby a solid was obtained. The material was cooled down to a temperature of 27±2C. To this 200 ml of ethyl acetate was added, followed by chilling the reaction mixture at a temperature of 3±2C. The solid obtained was filtered and washed with 1 volume of ethyl acetate. The solid was then exposed to drying process under vacuum at 27±2C for 2 hours. The material was powdered and again exposed to drying process under vacuum (630±20 mm of Hg) at 53±2C for 4 hours. The drying process was continued till the LOD (loss on drying) was less than 0.5%w/w to obtain the title compound. Dry weight: lOOgms Yield: 87.8% HPLC Purity: 99. 9%
74.3% With potassium fluoride; sulfuric acid; In ethanol; n-heptane; at 15 - 37℃; for 8.25h; EXAMPLE 3 <strong>[198904-31-3]Atazanavir</strong> Bisulfate-Form E3 (Triethanol Solvate) <strong>[198904-31-3]Atazanavir</strong> free base (prepared as described in Example 1, Part C) (3.0 g, 4.26 mmol) was slurried in dry, 200 proof ethanol (20.25 mL, 6.75 mL/g of free base) in a 100 mL, 3-neck round-bottom flask fitted with a mechanical stirrer, temperature probe, and a pressure-equalizing liquid addition funnel. Concentrated H2SO4 (0.25 mL, 0.46 g, 4.69 mmol, 1.1 eq.) was added to the slurry of <strong>[198904-31-3]atazanavir</strong> free base which was maintained at 20-25 C. The resulting solution (KF of 0.2 to 1.0% water) was polish filtered (Whatman #1 paper), the filter rinsed with 2.25 mL of absolute ethanol and the rinse added to the filtered solution. The solution was heated to 37 C. and seeded with 10 mg of amorphous <strong>[198904-31-3]atazanavir</strong> bisulfate derived from Form E3 crystals (by exposing Form E3 crystals to ambient temperature), and the mixture was agitated for 15 min. Heptane (380 mL, 8.25 mL/g of free base) was added over 1 hour. The resulting crystallization mixture was agitated for 8 h at 15-25 C. Crystallized <strong>[198904-31-3]atazanavir</strong> bisulfate was filtered on a Buchner funnel. The product cake was washed with 184 mL (4 mL/g of free base) of 1:1 ethanol: heptane. The product cake was washed with 46 mL (1 mL/g of free base) of heptane. The resulting product was dried under vacuum at 40-50 C. until it had an LOD=0.97%. The yield of product was 47.7 g (0.0594 mol, 74.3 mol %) of <strong>[198904-31-3]atazanavir</strong> bisulfate Form E3 (triethanol solvate) with HPLC HI=100.0 (see FIGS. 9 and 10).
With sulfuric acid; In 1-methyl-pyrrolidin-2-one; acetone; at 20 - 50℃; for 7h; E. 1-[4-(Pyridin-2-yl)phenyl]-5(S)-2,5-bis [N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane bisulfate salt About 10% (2 g) of the total charge of concentrated sulfuric acid (19 g, 1.10 eq.) was added to the free base acetone/N-methylpyrrolidone solution of Part D, while maintaining the temperature at 40-50 C., via subsurface addition. The reaction mixture was seeded with 5.0 wt % (wrt calculated free base in solution) of bisulfate salt. The seeded mixture was agitated at 40-50 C. for at least 30 minutes during which time the bisulfate salt began crystallizing as evidenced by the mixture increasing in opacity during this time. The remaining sulfuric acid (17.8 g) was added over ca. 5 h in five stages according to the following protocol, defined by a cubic equation, while keeping the temperature at 40-50 C. The rate of each addition stage was determined according to the cubic equation described hereinbefore and is shown in the table below. TABLE 1 Stage mL/kg/h mL(H2SO4)/h g(H2SO4)/h Duration (min) 1 4.62 0.579 1.065 60 2 6.93 0.868 1.597 60 3 16.55 2.073 3.814 60 4 30.26 3.790 6.974 60 5 48.47 6.071 11.171 23 After addition of H2SO4 was complete, the slurry was cooled to 20-25 C. for at least 1 h with agitation. The slurry was agitated at 20-25 C. for at least 1 h. The bisulfate salt was filtered and the mother liquor was recycled as needed to effect complete transfer. The filter cake was washed with acetone (5-10 mL/g of free base; 1200 mL acetone). The bisulfate salt was dried at NMT 55 C. under vacuum until the LOD<1% to produce a crystalline material. The crystalline product was analyzed by PXRD, DSC and TGA patterns and SSNMR spectrum and found to be (non-solvated) Form A crystals of the title bisulfate (see FIGS. 1 to 5).
With sulfuric acid; In ethanol; at 25 - 30℃; for 0.666667h;Industry scale; To a solution of <strong>[198904-31-3]atazanavir</strong> base (60 Kg) in ethanol (390 L), concentrated sulfuric acid (5.16 L) was added at 25 - 30C and stirred for 40 minutes. To the solution n-heptane (498 L) and seed of <strong>[198904-31-3]atazanavir</strong> sulfate ( 80 g) were added. Stirred at 25 - 30C for 16 hours. The solid was filtered, washed with 1 : 1 mixture of ethanol: n-heptane and dried to give 58 Kg of <strong>[198904-31-3]atazanavir</strong> sulfate. (HPLC data: <strong>[198904-31-3]atazanavir</strong> sulfate - 99.93%, RSSS isomer - 0.01%, SSSR isomer - 0,01 %, RSSR isomer - below detection limit).
With sulfuric acid; In acetone; at 40 - 45℃; Example 7: Preparation of <strong>[198904-31-3]Atazanavir</strong> Bisulfate (1 : 1) Formula I To <strong>[198904-31-3]atazanavir</strong> (150 g; obtained in Example 6), dichloromethane (900 mL) and N- methylpyrrolidine (188 mL) were added under stirring at ambient temperature and further stirred for 30 minutes to 40 minutes. After the solution became clear, activated carbon (7.5 g) was added and further stirred for 30 minutes to 40 minutes at ambient temperature. The reaction mixture was filtered through a hyflo-bed and the bed was washed twice with dichloromethane (2 x 150 mL). The filtrates were combined, heated to 40C to 45C and dichloromethane was recovered atmospherically. Sequentially, acetone (2 x 750 mL) was added to the reaction mass, the solution so obtained was heated to 60C to 65C and acetone was recovered atmospherically and then vacuum was applied for 30 minutes to 45 minutes at 60C to 65C. After that, acetone (2400 mL) was added at the same temperature and then cooled to 40C to 45C. Concentrated sulfuric acid (22.96 g) was slowly added over a period of 3 hours to 4 hours at 40C to 45C and stirred for 30 minutes to 40 minutes. The reaction mixture was cooled to 20C to 25C and stirred for 3 hours to 4 hours at 20C to 25C. The solid was filtered and acetone (1200 mL) was added at 20C to 25C to the wet cake and stirred for 15 minutes to 20 minutes. The solid was filtered, washed with acetone (150 mL) and dried under vacuum at 45C to 50C to afford the title compound. Yield(w/w): 1.03
Example 7 Preparation of <strong>[198904-31-3]Atazanavir</strong> Bisulfate (1:1) To <strong>[198904-31-3]atazanavir</strong> (150 g; obtained in Example 6), dichloromethane (900 mL) and N-methylpyrrolidine (188 mL) were added under stirring at ambient temperature and further stirred for 30 minutes to 40 minutes. After the solution became clear, activated carbon (7.5 g) was added and further stirred for 30 minutes to 40 minutes at ambient temperature. The reaction mixture was filtered through a hyflo-bed and the bed was washed twice with dichloromethane (2*150 mL). The filtrates were combined, heated to 40 C. to 45 C. and dichloromethane was recovered atmospherically. Sequentially, acetone (2*750 mL) was added to the reaction mass, the solution so obtained was heated to 60 C. to 65 C. and acetone was recovered atmospherically and then vacuum was applied for 30 minutes to 45 minutes at 60 C. to 65 C. After that, acetone (2400 mL) was added at the same temperature and then cooled to 40 C. to 45 C. Concentrated sulfuric acid (22.96 g) was slowly added over a period of 3 hours to 4 hours at 40 C. to 45 C. and stirred for 30 minutes to 40 minutes. The reaction mixture was cooled to 20 C. to 25 C. and stirred for 3 hours to 4 hours at 20 C. to 25 C. The solid was filtered and acetone (1200 mL) was added at 20 C. to 25 C. to the wet cake and stirred for 15 minutes to 20 minutes. The solid was filtered, washed with acetone (150 mL) and dried under vacuum at 45 C. to 50 C. to afford the title compound.
With sulfuric acid; In 1-methyl-pyrrolidin-2-one; acetone; at 40 - 50℃; for 0.5h; About 10% (2 g) of the total charge of concentrated sulfuric acid (19 g, 1.10 eq.) is added to the free base acetoneN-methylpyrrolidone solution of Part D, while maintaining the temperature at 40-50 C., via subsurface addition. The reaction mixture is seeded with 5.0 wt % (wrt calculated free base in solution) of sulfate salt. The seeded mixture is agitated at 40-50 C. for at least 30 minutes during which time the sulfate salt began crystallizing as evidenced by the mixture increasing in opacity during this time. The remaining sulfuric acid (17.8 g) is added over ca. 5 h in five stages according to the following protocol, defined by a cubic equation, while keeping the temperature at 40-50 C. The rate of each addition stage is determined according to the cubic equation described in U.S. Patent Publication No. U520050256202A1, published Nov. 17, 2005. After addition of H2504 is complete, the slurry is cooled to 20-25 C. for at least 1 h with agitation. The slurry is agitated at 20-25 C. for at least 1 h. The sulfate salt is filtered and the mother liquor is recycled as needed to effect complete transfet The filter cake is washed with acetone (5-10 mEg of free base; 1200 mE acetone). The sulfate salt is dried at NMT 55 C. under vacuum until the LOD<1% to produce a crystalline material.

  • 16
  • [ 869285-68-7 ]
  • 1-[4-(Pyridin-2-yl)phenyl]-5(S)-2,5-bis[(tert-butyloxycarbonyl)amino]-4(S)-hydroxy-6-phenyl-2-azahexane.3hydrochloride [ No CAS ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
95 - 100% With dipotassium hydrogenphosphate; In water; at 5 - 40℃; for 1.5 - 2h; C. 1-[4-(Pyridin-2-yl)phenyl]-5(S)-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane (atazanavir free base) Anhydrous dibasic potassium phosphate (K2HPO4; 226 g., 1.30 mol, 7.30 eq. wrt protected triamine) was dissolved in 1130 mL of water (11.3 mL/g of protected amine; 5 mL/g of K2HPO4). The K2HPO4 solution was added to the active ester solution prepared in Part B. To the stirred active ester/aqueous K2HPO4 mixture was slowly added the aqueous solution of Part A hydrogen chloride salt over a period of 1.5 to 2.0 h while maintaining agitation and a pot temperature between 5 and 20 C. After the addition of the solution of the Part A hydrogen chloride salt was complete, the reaction mixture (coupling reaction) was heated to 30-40 C. and agitated until the coupling reaction was judged complete by HPLC assay. The coupling mixture was cooled to 15 to 20 C. and the lower, product rich organic phase was separated from the upper, spent aqueous phase. The product rich organic phase was washed with 1M NaH2PO4 (880 mL; pH=1.5; 8.8 mL/g of protected triamine input; 5 mole eq. wrt protected triamine), the phases were allowed to separate, and the spent aqueous phase was removed. The washed product rich organic phase was stirred with 0.5 N NaOH (800 mL; 8 mL/g of protected triamine input) until HPLC assay of the rich organic phase showed the active esters to be below 0.3 I.I. each. The phases were allowed to separate and the spent aqueous phase was removed. The rich organic phase was washed with 5% NaH2PO4 (450 mL, 4.5 mL/g of protected triamine input; pH=4.3), the phases were allowed to separate and the spent aqueous phase was removed. The rich organic phase was washed with 10 w/v % NaCl (475 mL, 4.75 mL/g of protected triamine input) and the spent aqueous phase was removed. The concentration of title free base in solution was 120 to 150 mg/mL with an in-process calculated yield of 95-100 mol %.
  • 17
  • N-methoxycarbonyl-(L)-tert-leucine [ No CAS ]
  • 1-[4-(pyridin-2-yl)phenyl]-4(S)-hydroxy-5(S)-2,5-diamino-6-phenyl-2-azahexane trihydrochloride [ No CAS ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
In ethanol; dichloromethane; water; ethyl acetate; 1-[4-(Pyridin-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-bis[N-(N-methoxycarbonyl-(L)-tert-leucyl)-amino]-6-phenyl-2-azahexane With the exclusion of moisture, 567 g (3.0 mol) of N-methoxycarbonyl-(L)-tert-leucine (Example 5b)) and 891 g (3.0 mol) of TPTU are introduced into 3 liters of methylene chloride; with ice-cooling, 775 g (6 mol) of Hunig base are added dropwise and the mixture is stirred for 20 min. A suspension of 432 g (1.0 mol) of 1-[4-(pyridin-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-diamino-6-phenyl-2-azahexane trihydrochloride in 3 liters of methylene chloride is then added to the solution and the mixture is stirred at room temperature over-night to complete the reaction. The reaction mixture is washed with 10 liters of water, 10 liters of sat. NaHCO3 solution and 5 liters of brine. The aqueous phases are extracted a further 2* with 5 liters of methylene chloride, and the organic phases are dried (Na2 SO4) and concentrated by evaporation. The residue is dissolved in 6 liters of ethyl acetate and filtered through 500 g of silica gel; the column is then washed with 6 liters of ethyl acetate and the product-containing fractions are concentrated by evaporation. Stirring in boiling DIPE/ethanol 49:1 (9 liters; 1 h), cooling and filtration yield the title compound which can be purified further by recrystallisation from ethanol/water (m.p. 207-209 C.). The starting material is prepared as follows:
In ethanol; dichloromethane; water; ethyl acetate; Example 46* 1-[4-(Pyridin-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-bis[N-(N-methoxycarbonyl-(L)-tert-leucyl)amino]-6-phenyl-2-azahexane With the exclusion of moisture, 567 g.(3.0 mol) of N-methoxycarbonyl-(L)-tert-leucine (Example 2e) and 891 g (3.0 mol) of TPTU are placed in 3 litres of methylene chloride; with ice-cooling, 775 g (6 mol) of Hunig base are added dropwise and the mixture is stirred for 20 min. A suspension of 432 g (1.0 mol) of 1-[4-(pyridin-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-diamino-6-phenyl-2-azahexane trihydrochloride in 3 itres of methylene chloride is then added to the solution and the mixture is stirred at room temperature overnight to complete the reaction. The reaction mixture is washed with 10 litres of water, 10 litres of sat. NaHCO3 solution and 5 litres of brine. The aqueous phases are extracted a further 2* with 5 litres of methylene chloride; the organic phases are dried (Na2 SO4) and concentrated by evaporation. The residue is dissolved in 6 litres of ethyl acetate and filtered through 500 g of silica gel; the column is rinsed with 6 litres of ethyl acetate and the product-containing fractions are concentrated by evaporation. Stirring in boiling DIPE/ethanol 49:1 (9 litres; 1 hour), cooling and filtration yield the title compound, which can be further purified by recrystallisation from ethanol/water (m.p. 207-209 C.).
YieldReaction ConditionsOperation in experiment
Example 46 1-[4-(Pyridin-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-bis[N-(N-methoxy-carbonyl-(L)-tert-leucyl)amino]-6-phenyl-2-azahexane Process A: With the exclusion of moisture, 10.85 g of N-methoxycarbonyl-(L)-tert-leucine (Example 2e) and 17.1 g of TPTU are placed in 65 ml of DMF. 35.1 ml of Hunig base are added to the white suspension and the mixture is stirred at room temperature for 20 min. Then 13.2 g (26 mmol) of 1-?4-(pyridin-2-yl)[-phenyl]-4(S)-hydroxy-5(S) -2,5-diamino-6-phenyl-2-azahexane hydrochloride (Example 37f) dissolved in 65 ml of DMF are added and the mixture is stirred for 24 hours to complete the reaction (after 20 hours, a further 5 ml of Hunig base are added). The reaction mixture is poured into 600 ml of water and the resulting precipitate is filtered off and washed with water. The filter residue is then dissolved in methylene chloride and washed 2* with sat. NaHCO3 solution, water and brine. After drying over sodium sulfate and concentration, the resulting foam is digested with DIPE; the solid is filtered off and dried. The resulting crude product is dissolved again in methylene chloride, treated with active carbon and, after filtration, precipitated with ether. The resulting title compound is dried in a heated desiccator at 40 C. under a high vacuum: m.p.: 202-204 C.; TLC: Rt =0.38 (ethyl acetate); HPLC20-100: tRet =11.81; FAB MS (M+H)+ =705. Further product can be obtained from the mother liquor after chromatography (SiO2, hexane/ethyl acetate, then ethyl acetate) and after crystallisation from ether (m.p. 206-207 C.).
IF "YES?: Are you taking any of the following? a. Amprenavir b. Atazanavir c. Delavirdine d. Fosamprenavir e. Indinavir f. Nelfinavir
  • 19
  • [ 1028634-76-5 ]
  • [ 79-22-1 ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0℃; for 2.5h; Example 6 - Preparation of Atazanavir Compound (8) (9.47 g), obtained according to example 5, was suspended in 200 mL of CH2Cl2, added with 1.99 g of diisopropyl ethylamine, and the resulting mixture was cooled to about 0C. 1.45 g of methyl chloroformate in 25 mL of CH2Cl2 were added dropwise over about 2 hours. The suspension was then stirred for about half an hour at 0C and added with an aqueous solution of 10% NaHCO3 (100 mL) at 0C with vigorous stirring. The organic phase was the separated, dried over anhydrous sodium sulphate, filtered and evaporated in vacuo to afford 8.46 g of a white solid, which was hot-crystallized from ethanol (65 mL) and water (33 mL). The resulting solid was filtered, washed on the filter with an ethanol/water mixture and dried, to obtain 5.1.g of Atazanavir as a white solid.
  • 20
  • [ 857904-02-0 ]
  • [ 1192510-20-5 ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
87% In dichloromethane; for 64h;Silica gel; Example 8; Atazanavir (1) A suspension of (2R,3S)-1,2-Epoxy-3-[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4-phenylbutane (2) (334 mg, 1 mmol), N-[N-(Methoxycarbonyl)-L-tert-leucinyl]-N'-[4-(2-pyridyl)phenylmethyl]hydrazine (3) (370 mg, 1 mmol) and silica gel (1.0 g) in CH2Cl2 (3 mL) was stirred for 64 h. The mixture was diluted with EtOAc (10 mL), filtered and washed with a mixture of EtOAc-CH2Cl2 (1:1). The filtrate was concentrated under reduced pressure. The residue was crystallized from EtOAc-hexane to give the product (613 mg, 87%) as colorless crystals.
87% silica gel; In dichloromethane; for 64h; A suspension of (2i?,3S)-l,2-Epoxy-3-[N-(methoxycarbonyl)-L-te/t- leucinyl] amino }-4-phenylbutane (2) (334 mg, 1 mmol), N-[N-(M ethoxycarbonyl)-L-te/t- leucinyl]-N'-[4-(2-pyridyl)phenylmethyl] hydrazine (3) (370 mg, 1 mmol) and silica gel (1.0 g) in CH2Cl2 (3 mL) was stirred for 64 h. The mixture was diluted with EtOAc (10 mL), filtered and washed with a mixture Of EtOAc-CH2Cl2 (1 : 1). The filtrate was concentrated under reduced pressure. The residue was crystallized from EtOAc-hexane to give the product (613 mg, 87%) as colorless crystals.
In isopropyl alcohol; at 90℃; for 12h; (102.0g, 305.0mmol) a compound of formula (S) -1 - (( S) -2-epoxy-2-ethyl-1-phenylethane - amino) -3,3-dimethyl Methyl-1-carbonylbutan-2-yl-carbamate and (122.2 g, 330.0 mmol) Compound N-1-[N-(methoxycarbonyl)-L-tert-leucine]-N- Dissolve 2-[4-(2-pyridyl)-benzyl]hydrazine in 500 ml of isopropanol, reflux at 90 C for 12 hours, cool, slowly add 1000 ml of distilled water, stir for 2 hours, stand, filter, wash and reuse. recrystallisation from aqueous ethanol, vacuum drying, the liquid phase is detected, to give 201.3g of formula compound 1- [4- (2-pyridyl) phenyl] -5 (S) -2,5- bis [N- (methyl oxygen-carbonyl) -L- tert-leucine-yl] amino} -4 (S) - hydroxy-6-phenyl-2-aza-hexane VIII, namely atazanavir.
  • 21
  • (2S,3S)-3-amino-4-phenyl-1-(1-(4-(pyridin-2-yl)benzyl)hydrazinyl)butan-2-ol hydrochloride [ No CAS ]
  • [ 162537-11-3 ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
To another flask N-methoxycarbonyl-(L)-tertiary leucine (V) (88.1 1 g, 0.47 mole), 1- (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (89.4 g, ' 0.47 mole), 1 -Hydroxy-benzotriazole (HOBT) (75.5 g, 0.49 mole) and dichloromethane (1000 mL) were charged and stirred at 25 - 30C for 4 - 5 hours. The aqueous layer of diamino compound (IV) obtained above in part A, and N, N-diisopropylethyl amine (DIPEA) (182.8 mL, 138 g) were added and stirred for 3 hours. The reaction mass was then washed with water, sodium bicarbonate solution and brine. The dichloromethane layer was concentrated to 100 - 150 ml_. Ethyl acetate (1000 ml.) was added and about half of the mixture of solvent was distilled out. n-Heptane (400 mL) was added and stirred for 1 hour at 65C. Cooled to 30C, solid was filtered, washed with mixture of ethyl acetate and n-heptane and dried to afford 101' g of atazanavir base (crude).
YieldReaction ConditionsOperation in experiment
In ethanol; water; at 80 - 85℃;Industry scale;Purification / work up; <strong>[198904-31-3]Atazanavir</strong> base (100 Kg, 142 mole) was added in 700 L ethanol and stirred at 80 - 85C for 40 - 50 minutes. Water (700 L) was added in hot condition. Cooled to room temperature. Solid was filtered, washed with 1 : 1 mixture of ethanol-water and dried to afford 90 Kg of pure <strong>[198904-31-3]atazanavir</strong> base. (HPLC data: <strong>[198904-31-3]atazanavir</strong> - 99.98%, RSSS isomer - 0.01 %, SSSR isomer - below detection limit, RSSR isomer - below detection limit).
  • 23
  • [ 1192510-20-5 ]
  • [ 198904-31-3 ]
  • 24
  • [ 198905-04-3 ]
  • [ 198904-31-3 ]
  • 25
  • [ 162537-11-3 ]
  • 1-[4-(pyridine-2-yl)-phenyl]-4(S)-hydroxy-2-amino-5(S)-N-(N-methoxycarbonyl-(L)-tert-leucyl)amino-6-phenyl-2-azahexane dihydrochioride [ No CAS ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
Example 6: Preparation of Atazanavir Formula IX To N-methoxycarbonyl-(L)-tert-leucine (65.72 g), 1 -hydroxybenzotriazole (HOBT; 51.19 g) was added at ambient temperature under nitrogen atmosphere and the reaction mixture was cooled to 0C to -5C. Triethylamine (79.81 g) was slowly added to the reaction mixture at 0C to -5C and further dichloromethane (1600 mL) was added at ambient temperature. Thionyl chloride (43.20 g) was slowly added over a period of 1 hour to 1.5 hours at 0C to -5C under nitrogen atmosphere and the reaction mixture was stirred at 10C to 15C for 1.5 hours to 2 hours. De-ionized water (1000 mL) was added and the reaction mixture was stirred for 10 minutes to 15 minutes at 10C to 15C. The organic layer was separated and dipotassium hydrogen orthophosphate (K2HPO4; 480g/2000 mL de-ionized water) was added at 10C to 15C. The aqueous layer of dihydrochloride salt of l-[4-(pyridine-2-yl)-phenyl]-4(S)-hydroxy-2-amino-5(S)-N-(N-methoxycarbonyl-(L)- tert-leucyl)amino-6-phenyl-2-azahexane (as obtained in Example 5) was added to the organic layer over a period of 1.5 hours to 2 hours at 10C to 15C. This reaction mixture was stirred for 12 hours to 14 hours at 30C to 35C. The completion of the reaction was monitored by HPLC. After completion of the reaction, the reaction mixture was cooled to 20C to 25C and the organic layer was separated. The organic layer was sequentially washed with an aqueous solution of potassium hydrogen sulfate (20 g/1000 mL de-ionized water), an aqueous solution of potassium carbonate (120 g/1000 mL de-ionized water) and de-ionized water (1000 mL). The organic layer so obtained was heated to 40C to 45C to recover dichloromethane atmospherically and then vacuum was applied for 50 minutes to 60 minutes at the same temperature. Methanol (1400 mL) was added to the mass so obtained at 40C to 45C and the reaction mixture was further heated to 60C to 68C. De-ionized water (1200 mL) was slowly added over a period of 30 minutes to 45 minutes at 60C to 68C. The reaction mixture was heated to reflux at 72C to 78C for 30 minutes. The reaction mixture was cooled to 20C to 25C and stirred for 2 hours to 3 hours. The solid was filtered and the wet cake was washed with a mixture of methanol (200 mL) and de-ionized water (200 mL). The solid so obtained was washed with toluene (1000 mL) and dried at 60C to 65C to afford the title compound. Yield(w/w): 1.0
Example 6 Preparation of Atazanavir To N-methoxycarbonyl-(L)-tert-leucine (65.72 g), 1-hydroxybenzotriazole (HOBT; 51.19 g) was added at ambient temperature under nitrogen atmosphere and the reaction mixture was cooled to 0 C. to -5 C. Triethylamine (79.81 g) was slowly added to the reaction mixture at 0 C. to -5 C. and further dichloromethane (1600 mL) was added at ambient temperature. Thionyl chloride (43.20 g) was slowly added over a period of 1 hour to 1.5 hours at 0 C. to -5 C. under nitrogen atmosphere and the reaction mixture was stirred at 10 C. to 15 C. for 1.5 hours to 2 hours. De-ionized water (1000 mL) was added and the reaction mixture was stirred for 10 minutes to 15 minutes at 10 C. to 15 C. The organic layer was separated and dipotassium hydrogen orthophosphate (K2HPO4; 480 g/2000 mL de-ionized water) was added at 10 C. to 15 C. The aqueous layer of dihydrochloride salt of 1-[4-(pyridine-2-yl)-phenyl]-4(S)-hydroxy-2-amino-5(S)-N-(N-methoxycarbonyl-(L)-tert-leucyl)amino-6-phenyl-2-azahexane (as obtained in Example 5) was added to the organic layer over a period of 1.5 hours to 2 hours at 10 C. to 15 C. This reaction mixture was stirred for 12 hours to 14 hours at 30 C. to 35 C. The completion of the reaction was monitored by HPLC. After completion of the reaction, the reaction mixture was cooled to 20 C. to 25 C. and the organic layer was separated. The organic layer was sequentially washed with an aqueous solution of potassium hydrogen sulfate (20 g/1000 mL de-ionized water), an aqueous solution of potassium carbonate (120 g/1000 mL de-ionized water) and de-ionized water (1000 mL). The organic layer so obtained was heated to 40 C. to 45 C. to recover dichloromethane atmospherically and then vacuum was applied for 50 minutes to 60 minutes at the same temperature. Methanol (1400 mL) was added to the mass so obtained at 40 C. to 45 C. and the reaction mixture was further heated to 60 C. to 68 C. De-ionized water (1200 mL) was slowly added over a period of 30 minutes to 45 minutes at 60 C. to 68 C. The reaction mixture was heated to reflux at 72 C. to 78 C. for 30 minutes. The reaction mixture was cooled to 20 C. to 25 C. and stirred for 2 hours to 3 hours. The solid was filtered and the wet cake was washed with a mixture of methanol (200 mL) and de-ionized water (200 mL). The solid so obtained was washed with toluene (1000 mL) and dried at 60 C. to 65 C. to afford the title compound.
  • 26
  • [ 162536-40-5 ]
  • [ 198904-31-3 ]
  • 27
  • [ 369362-96-9 ]
  • [ 198904-31-3 ]
  • 28
  • methyl [(2S)-1-[(2S,3R)-4-chloro-3-hydroxy-1-phenylbutan-2-yl]amino}-3,3-dimethyl-1-oxobutan-2-yl]carbamate [ No CAS ]
  • [ 198904-31-3 ]
  • 29
  • sodium 7‐azido‐1,1‐difluoroheptane‐1‐sulfinate [ No CAS ]
  • [ 198904-31-3 ]
  • [ 1450912-80-7 ]
  • [ 1450912-81-8 ]
  • 30
  • [ 149451-80-9 ]
  • [ 198904-31-3 ]
  • 31
  • [ 437713-03-6 ]
  • [ 198904-31-3 ]
  • 32
  • [ 87199-17-5 ]
  • [ 198904-31-3 ]
  • 33
  • C16H25NO6S [ No CAS ]
  • [ 198904-31-3 ]
  • 34
  • [ 198904-84-6 ]
  • [ 198904-31-3 ]
  • 35
  • [ 857904-00-8 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 36
  • [ 857904-00-8 ]
  • [ 198904-31-3 ]
  • 37
  • [ 198904-77-7 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 38
  • [ 198904-77-7 ]
  • [ 198904-31-3 ]
  • 39
  • [ 1122-91-4 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 40
  • [ 1122-91-4 ]
  • [ 198904-31-3 ]
  • 41
  • [ 857904-02-0 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 42
  • [ 1033125-49-3 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 43
  • [ 1033125-49-3 ]
  • [ 198904-31-3 ]
  • 44
  • [ 1003888-24-1 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 45
  • [ 1003888-24-1 ]
  • [ 198904-31-3 ]
  • 46
  • methyl (S)-1-((S)-4-chloro-3-oxo-1-phenylbutan-2-ylcarbamoyl)-2,2-dimethylpropyl carbamate [ No CAS ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 47
  • methyl (S)-1-((S)-4-chloro-3-oxo-1-phenylbutan-2-ylcarbamoyl)-2,2-dimethylpropyl carbamate [ No CAS ]
  • [ 198904-31-3 ]
  • 48
  • L-phenylalanine chloromethyl ketone [ No CAS ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 49
  • L-phenylalanine chloromethyl ketone [ No CAS ]
  • [ 198904-31-3 ]
  • 50
  • [ 20859-02-3 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 51
  • 1-[4-(pyridin-2-yl)phenyl]-5(S)-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4-oxo-6-phenyl-2-azahexane [ No CAS ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 52
  • 1-[4-(pyridin-2-yl)phenyl]-5(S)-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4-oxo-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
70% With sodium tetrahydroborate; In 2-methyltetrahydrofuran; for 4h;Cooling with ice; Under ice-cooling, sodium borohydride (3.3 g, 87.5 mmol) was slowly added to a solution of compound IV (24.6 g, 35.0 mmol) in dry 2-methyltetrahydrofuran (400 ml) and stirred for 4 h. The reaction system was treated with water (2 ml). Extraction. The 2-methyltetrahydrofuran was spin-dryed under reduced pressure, and the system was diluted with dichloromethane (500 ml) and water (500 ml). Stir vigorously until a white flocculent precipitate has formed and filter. After extraction, the aqueous phase was extracted twice with dichloromethane (200 ml) and the organic phases were combined and washed with saturated brine (500 ml). The mixture was dried and concentrated to give crude product. After adding isopropyl ether/ethanol = 98:2 (368 ml), refluxed to a white syrupy emulsion, which was cooled and filtered to obtain crude product (18 g). 1 g of crude product was selected and recrystallized with ethanol/water=7.5:5.5 (13 ml) to obtain atazanavir, 0.9 g, yield 70%, purity 99.7 %
  • 53
  • [ 162537-11-3 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 54
  • [ 24856-58-4 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 55
  • [ 127406-56-8 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 56
  • [ 102123-74-0 ]
  • 1-[4-(pyridin-2-yl)phenyl]-2,5-bis[N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane [ No CAS ]
  • [ 198904-31-3 ]
  • 57
  • [ 102123-74-0 ]
  • [ 198904-31-3 ]
  • 58
  • [ 198904-31-3 ]
  • (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyrimidinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate dimethyl sulfate [ No CAS ]
YieldReaction ConditionsOperation in experiment
75.5% A) room temperature (25 C) free base is the compound (100.0g, 142mmol) and ethanol (750 ml) by adding the three-hole bottle (1000 ml) in, temperature-keeping 25-30oC stirring 30 minutes, reaction of white or white suspension maching, dropping slowly adding concentrated sulfuric acid to the reaction solution (8.6 ml, 0 . 05 ml/s), gradually become clarified solution, heating the solution to 35-40oC, E ethanol is added as seed crystal-type crystalline compound (4.26 mmol), stirring 15-20min, n-heptane is added to 750 ml (1 hours) stirring, cooling to 15-25oC, the generated crystallization mixture stirring 6-8 hours, filtering and collecting the solid, the filter cake is washed with ethanol/n-heptane = 1:1 (10 ml) washing, drying, shall be about 102g white or kind of white powdery solid composition of ethanol is E-type crystallization, HPLC purity 99.90%, the maximum shan Za 0.03%, diastereoisomers and enantiomers has not detected; and solvent residue GC TGA (0-180 C) ethanol in weightlessness display elements for the binding capacity of the 9.3%. ;B) 20 C ethanol compound is the compound under E-type crystallization (100g, 124.5mmol) and acetone (1.5L) by adding the three-hole bottle (2L) in, agitating beating 30 min, a solution is completely dissolved process, subsequently separating white crystal. Heating to reflux, reflux beating 2h. Natural cooling to 10-20C, to continue stirring crystallization, beating 5 hours, filtering and collecting the solid, the filter cake with acetone (100 ml), normal heptane (100 ml) washing, decompression 50-60 C after drying, to obtain 86g white or yellowish <strong>[198904-31-3]atazanavir</strong> bisulfate scobicular A type crystal, two-step yield 75.5%, HPLC purity of 99.97%, the maximum shan Za 0.01%.
  • 59
  • 1-[4-(pyridine-2-yl)-phenyl]-4(S)-hydroxy-(5S)-2,5-diamino-6-phenyl-2-azahexane [ No CAS ]
  • [ 162537-11-3 ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
91.6% With pyridine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; at 35℃; for 1.5h; At 35 & lt; 0 & gt; C,A solution of 1- [4- (pyridin-2-yl) -phenyl] -4 (S) -hydroxy-5 (S) -2,5-diamino-6-phenyl-2-azacyclohexane (100 mmol), N-methoxycarbonyl-L-tert-leucine (37.8 g, 200.0 mmol)76.0 g (200 mmol) of HATU and 71.2 g of pyridine were placed in a 500 mL eggplant vial,Add 200mL methyl isobutyl ketone stirring 1h, TLC detection, reaction completed,The reaction solution was washed with 10% potassium dihydrogen phosphate and purified water in an order of 200 mL x 2, and the aqueous layer was discarded,The organic phase was dried over anhydrous sodium sulfate for 6 h and then filtered, and the filtrate was heated to 50 C,While adding 0.4g of charcoal charcoal 767 for decolorization, stirring 20min, cold to 20-30 filter,The organic phase was concentrated in vacuo,To the above oil was added 300 mL of ethanol and heated to reflux at 80 C to dissolve it all,And then 300mL of petroleum ether added to the hot solution, after the end of the natural cooling to 20-30 , and stirring 24h,The filter cake was washed twice with 30 mL of a mixed solvent of ethanol / petroleum ether = 1: 1, dried at 55 C for 12 h,64.5 g of finished azazanavir monomer, yield 91.6%, purity 99.9%.
  • 60
  • [ 162537-11-3 ]
  • [ 437713-06-9 ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
74.2% To 100 mL of N-methoxycarbonyl-L-tert-leucine was placed in a 500 mL Erlenmeyer flask, 200 mL of methylene chloride was added and stirred to dissolve, and then triethylamine 70.5 g and 14.2 g (112. Ommol) of thionyl chloride were added and the temperature was raised to 42 C. The solvent was diluted with methylene chloride. The mixture was allowed to cool for 3 h. The reaction was completed and the temperature was reduced to room temperature. The triethylamine hydrochloride solid was removed by filtration.use.The solid product (32.58 g, 90 mmol) in Example 1 was dissolved in 50 mL of dichloromethane, and the filtrate was slowly added dropwise to the system at room temperature. The mixture was stirred overnight and the reaction was completed.The reaction solution was washed successively with 10% citric acid, 10% potassium carbonate, 10% sodium chloride and purified water to 300 mL of X, concentrated under reduced pressure to about dichloromethane content of less than about 20%, and 191.43 mL of methyl tert Butyl ether, beating, filtration, vacuum 50 C to dry 54.3 g of the crude azazavir monomer, and the crude product was purified in a 1: 1 by volume ratio of ethanol: water to give anazanavir monomer 47. 1g, yield 74.2%.
  • 61
  • [ 198904-31-3 ]
  • 1-[4-(pyridin-2-yl)phenyl]-(S)-2,5-bis[N-(methoxycarbonyl)-L-tert-leucyl]amino}-4-(S)-hydroxy-6-phenyl-2-azahexane hydrobromide [ No CAS ]
YieldReaction ConditionsOperation in experiment
92.3% With hydrogen bromide; In acetone; at 20 - 55℃; for 2.5h; Compound I (<strong>[198904-31-3]atazanavir</strong>, 7.0 g) and acetone (50 mL) prepared in Referential Example 1 were added to a three-necked flask and warmed toHydrobromic acid (HBr content of 40 wt%, 2.2 g, 1.1 eq) was added in one portion at 55 DEG C for 1 hour, then slowly cooled to room temperature, stirred for 1.5 hours, filtered and dried under vacuum to obtain 7.2 g of white crystalline Of <strong>[198904-31-3]atazanavir</strong> hydrobromide (polymorph of <strong>[198904-31-3]atazanavir</strong> hydrobromide), yield 92.3%, HPLC: 99.7%, enantiomeric excess ?99.5%.
  • 62
  • [ 63-91-2 ]
  • [ 198904-31-3 ]
  • 63
  • C17H24N2O5 [ No CAS ]
  • [ 198904-31-3 ]
  • 64
  • C18H25BrN2O4 [ No CAS ]
  • [ 198904-31-3 ]
  • 65
  • C18H27BrN2O4 [ No CAS ]
  • [ 198904-31-3 ]
  • 66
  • [ 869285-68-7 ]
  • 1-[4-(pyridin-2-yl)phenyl]-4(S)-hydroxy-5(S)-2,5-diamino-6-phenyl-2-azahexane trihydrochloride [ No CAS ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
100% With dipotassium hydrogenphosphate; In water; at 5 - 40℃; Anhydrous dibasic potassium phosphate (K2HPO4226 g., 1.30 mol, 7.30 eq. wrt protected triamine) is dissolved in 1130 mE of water (11.3 mLg of protected amine; 5 mLg of K2HPO4). The K2HPO4 solution is added to the active ester solution prepared in Part S. To the stirred active ester aqueous K2HPO4 mixture is slowly added the aqueous solution of Part A hydrogen chloride salt over a period of 1.5 to 2.0 h while maintaining agitation and a pot temperature between 5 and 20 C. After the addition of the solution of the Part A hydrogen chloride salt is complete, the reaction mixture (coupling reaction) is heated to 30-40 C. and agitated until the coupling reaction is judged complete by HPLC assay. The coupling mixture is cooled to 15 to 20 C. and the lower, product rich organic phase is separated from the upper, spent aqueous phase. The product rich organic phase is washed with 1M NaH2PO4 (880 mE; pH=1.5; 8.8 mEg of protected triamine input; 5 mole eq. wrt protected triamine), the phases were allowed to separate, and the spent aqueous phase is removed. The washed product rich organic phase is stirred with 0.5 N NaOH (800 mE; 8 mEg of protected triamine input) until HPEC assay of the rich organic phase showed the active esters to be below 0.3 1.1. each. The phases were allowed to separate and the spent aqueous phase is removed. The rich organic phase is washed with 5% NaH2PO4 (450 mE, 4.5 mLg of protected triamine input; pH=4.3), the phases were allowed to separate and the spent aqueous phase is removed. The rich organic phase is washed with 10 wv % NaC1 (475 mE, 4.75 mLg of protected triamine input) and the spent aqueous phase is removed. The concentration of title free base in solution is120 to 150 mgmL with an in-process calculated yield of95-100 mol %.
  • 67
  • [ 13734-41-3 ]
  • [ 198904-31-3 ]
  • (2S,3S)-3-((S)-2-((methoxycarbonyl)amino)-3,3-dimethylbutanamido)-1-(2-((S)-2-((methoxycarbonyl)amino)-3,3-dimethylbutanoyl)-1-(4-(pyridin-2-yl)benzyl)hydrazinyl)-4-phenylbutan-2-yl (tert-butoxycarbonyl)-L-valinate [ No CAS ]
  • 68
  • [ 13734-41-3 ]
  • [ 198904-31-3 ]
  • (2S,3S)-3-((S)-2-((methoxycarbonyl)amino)-3,3-dimethylbutanamido)-1-(2-((S)-2-((methoxycarbonyl)amino)-3,3-dimethylbutanoyl)-1-(4-(pyridin-2-yl)benzyl)hydrazinyl)-4-phenylbutan-2-yl L-valinate dihydrochloride [ No CAS ]
  • 69
  • trametinib [ No CAS ]
  • [ 198904-31-3 ]
  • C90H96F2N16O15 [ No CAS ]
  • 70
  • [ 556-96-7 ]
  • [ 198904-31-3 ]
  • C54H68N6O7 [ No CAS ]
YieldReaction ConditionsOperation in experiment
146.1 mg With C17H24N5Ru(1+)*F6P(1-); potassium acetate; potassium carbonate; In 1-methyl-pyrrolidin-2-one; at 35℃; for 72h;Inert atmosphere; Glovebox; General procedure: Unless otherwise stated, in an Argon filled glove-box a crimp-cap microwave vial equipped with a magnetic stirring bar was charged with the appropriate cyclometalated Ru(ll)-catalyst (like Ru1-Ru46, from 3 mol % to 10 mol %), KOAc (5.9 mg, 0.06 mmol, 30 mol %), K2CO3 (2.0 - 4.0 equiv.), the appropriate DG-containing arene (like N1-N12, 0.20 mmol, 1.0 equiv.), the appropriate (hetero)aryl (pseudo)halide (like X1-X42, 0.2 mmol, 1.0 equiv) and /V-methyl-2- pyrrolidone (NMP) (200 pL, 1 M). The vial was capped and stirred at 35 C for 24 hours. Upon completion, the crude mixture was loaded on a silica gel column and purified by flash chromatography
  • 71
  • [ 198904-31-3 ]
  • [ 121-57-3 ]
  • atazanavir bis(4-aminobenzenesulfonic acid) [ No CAS ]
YieldReaction ConditionsOperation in experiment
With sodium hydrogencarbonate; In water; at 20 - 42℃; for 2h; 2) salt formation1 Preparation of the aqueous suspension of <strong>[198904-31-3]atazanavir</strong> Take the <strong>[198904-31-3]atazanavir</strong> treated by the step (1), add water, stir and mix to obtain the aqueous suspension of <strong>[198904-31-3]atazanavir</strong>; the volume ratio of the mass of the <strong>[198904-31-3]atazanavir</strong> to the water is 1mg: 3ml;4-Aminobenzenesulfonic acid aqueous solution is prepared by taking 4-aminobenzenesulfonic acid, adding water, stirring and mixing to obtain 4-aminobenzenesulfonic acid aqueous solution; 4-aminobenzenesulfonic acid mass to water volume ratio is 1 mg: 3 ml; (3)sodium bicarbonate aqueous solution is prepared by taking sodium bicarbonate, adding water, stirring and mixing to obtain an aqueous solution of sodium hydrogencarbonate; the mass ratio of sodium bicarbonate to water is 1:0.8 ml;4 salt formation reactionTo the aqueous suspension of <strong>[198904-31-3]atazanavir</strong> prepared in step 1, the aqueous solution of sodium hydrogencarbonate prepared in step 3 was added, stirred and mixed, and the temperature was raised to 42 C under stirring, and slowly added by a peristaltic pump (addition rate of 50 mul/min) to step 2 Prepared aqueous solution of 4-aminobenzenesulfonic acid, after the reaction was completed, it was cooled to room temperature and kept at room temperature for 2 hr.Filter the filtrate,Concentration (nitrogen blowing) at 25 C to remove the solvent to obtain <strong>[198904-31-3]atazanavir</strong> di 4-aminobenzenesulfonate; <strong>[198904-31-3]atazanavir</strong>,a molar ratio of 4-aminobenzenesulfonic acid to sodium hydrogencarbonate of 2.0:1:0.06;5 After the treatment, take the <strong>[198904-31-3]atazanavir</strong> di 4-aminobenzenesulfonate obtained in step 4, add ethanol, stir, filter the filtrate, concentrate at 25 C (nitrogen blowing) to remove the solvent, and obtain <strong>[198904-31-3]atazanavir</strong> II. 4-Aminobenzenesulfonate; the mass ratio of <strong>[198904-31-3]atazanavir</strong> di 4-aminobenzenesulfonate to ethanol was 1 mg: 8 ml; the above procedure was carried out at room temperature unless otherwise specified, and the room temperature was 25 C. The XRPD pattern of <strong>[198904-31-3]atazanavir</strong> di 4-aminobenzenesulfonate of Example 1 is shown in Figure 1, which is Form A; nuclear magnetic identification determines salt formation, and <strong>[198904-31-3]atazanavir</strong> di 4-aminobenzenesulfonate The molar ratio of <strong>[198904-31-3]atazanavir</strong> to 4-aminobenzenesulfonic acid was 1:2; the purity by HPLC was 99.5%, and no residual organic solvent was detected.
  • 72
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (S)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-methylbutanoate [ No CAS ]
  • 73
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (R)-2-((R)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-methylbutanoate [ No CAS ]
  • 74
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (S)-2-((R)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-methylbutanoate [ No CAS ]
  • 75
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (R)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-3-methylbutanoate [ No CAS ]
  • 76
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (S)-2-((S)-2-amino-3-methylbutanamido)-3-methylbutanoate dihydrochloride [ No CAS ]
  • 77
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (R)-2-((R)-2-amino-3-methylbutanamido)-3-methylbutanoate dihydrochloride [ No CAS ]
  • 78
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (S)-2-((R)-2-amino-3-methylbutanamido)-3-methylbutanoate dihydrochloride [ No CAS ]
  • 79
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (R)-2-((S)-2-amino-3-methylbutanamido)-3-methylbutanoate dihydrochloride [ No CAS ]
  • 80
  • [ 198904-31-3 ]
  • atazanavir phosphate [ No CAS ]
  • 81
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-aminoacetate dihydrochloride [ No CAS ]
  • 82
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-(methylamino)acetate dihydrochloride [ No CAS ]
  • 83
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (S)-2-aminopropanoate dihydrochloride [ No CAS ]
  • 84
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl (R)-2-aminopropanoate dihydrochloride [ No CAS ]
  • 85
  • [ 198904-31-3 ]
  • disodium methyl ((5S,8S,9S,14S)-8-benzyl-5-(tert-butyl)-15,15-dimethyl-3,6,13-trioxo-9-((phosphonooxy)methoxy)-11-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,11,12-tetraazahexadecan-14-yl)-carbamate [ No CAS ]
  • 86
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)acetate [ No CAS ]
  • 87
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((S)-2-amino-3-phenylpropanamido)acetate dihydrochloride [ No CAS ]
  • 88
  • [ 198904-31-3 ]
  • (5S,10S,11S,14S)-11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((R)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)acetate [ No CAS ]
Same Skeleton Products
Historical Records